NK cells

Streamlining cell therapy manufacturing with CliniMACS Prodigy 2:08
Streamlining cell therapy manufacturing with CliniMACS Prodigy
Saskia Rösch • 6 Apr 2022
CAR T-cell therapy for neuroblastoma 2:24
CAR T-cell therapy for neuroblastoma
Shigeki Yagyu • 8 Apr 2022
Current developments in cell therapies for solid tumors 2:43
Current developments in cell therapies for solid tumors
Christopher Ballas • 27 Jan 2022
Liquid vs solid tumor strategies in cell therapy 2:17
Liquid vs solid tumor strategies in cell therapy
Kanya Rajangam • 13 Oct 2021
Advantages of allogeneic NK cell therapy 2:26
Advantages of allogeneic NK cell therapy
Kanya Rajangam • 13 Oct 2021
Targetting cancer with allogeneic NK cell therapies 3:05
Targetting cancer with allogeneic NK cell therapies
James Trager • 10 Mar 2021
CAR-NKs for B cell malignancies 2:09
CAR-NKs for B cell malignancies
James Trager • 10 Mar 2021
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC 3:24
CYAD-101 & alloSHRINK: allogeneic CAR-T cell therapy in MSS mCRC
David Gilham • 22 Feb 2021
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS 2:29
CYCLE-1: next generation NKG2D-based CAR T-cells in AML/MDS
David Gilham • 22 Feb 2021
The content of VJRegenMed is intended for healthcare professionals